Browse > Article
http://dx.doi.org/10.3344/kjp.2014.27.2.103

Rediscovery of Nefopam for the Treatment of Neuropathic Pain  

Kim, Kyung Hoon (Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University)
Abdi, Salahadin (Department of Pain Medicine, Division of Anesthesiology and Critical Care, The University of Texas MD Anderson Cancer Center)
Publication Information
The Korean Journal of Pain / v.27, no.2, 2014 , pp. 103-111 More about this Journal
Abstract
Nefopam (NFP) is a non-opioid, non-steroidal, centrally acting analgesic drug that is derivative of the nonsedative benzoxazocine, developed and known in 1960s as fenazocine. Although the mechanisms of analgesic action of NFP are not well understood, they are similar to those of triple neurotransmitter (serotonin, norepinephrine, and dopamine) reuptake inhibitors and anticonvulsants. It has been used mainly as an analgesic drug for nociceptive pain, as well as a treatment for the prevention of postoperative shivering and hiccups. Based on NFP's mechanisms of analgesic action, it is more suitable for the treatment of neuropathic pain. Intravenous administration of NFP should be given in single doses of 20 mg slowly over 15-20 min or with continuous infusion of 60-120 mg/d to minimize adverse effects, such as nausea, cold sweating, dizziness, tachycardia, or drowsiness. The usual dose of oral administration is three to six times per day totaling 90-180 mg. The ceiling effect of its analgesia is uncertain depending on the mechanism of pain relief. In conclusion, the recently discovered dual analgesic mechanisms of action, namely, a) descending pain modulation by triple neurotransmitter reuptake inhibition similar to antidepressants, and b) inhibition of long-term potentiation mediated by NMDA from the inhibition of calcium influx like gabapentinoid anticonvulsants or blockade of voltage-sensitive sodium channels like carbamazepine, enable NFP to be used as a therapeutic agent to treat neuropathic pain.
Keywords
adverse drug reactions; molecular mechanisms of pharmacological action; nefopam; neuropathic pain; nonopioid analgesics;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Benzon HT. The neuropathic pain scales. Reg Anesth Pain Med 2005; 30: 417-21.   DOI
2 Mather GG, Labroo R, Le Guern ME, Lepage F, Gillardin JM, Levy RH. Nefopam enantiomers: preclinical pharmacology/toxicology and pharmacokinetic characteristics in healthy subjects after intravenous administration. Chirality 2000; 12: 153-9.   DOI
3 Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics 2009; 6: 703-12.   DOI   ScienceOn
4 Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch Neurol 2004; 61: 641-4.   DOI   ScienceOn
5 Durrieu G, Olivier P, Bagheri H, Montastruc JL; French Network of Pharmacovigilance Centers. Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database. Fundam Clin Pharmacol 2007; 21: 555-8.   DOI   ScienceOn
6 Verleye M, Andre N, Heulard I, Gillardin JM. Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents. Brain Res 2004; 1013: 249-55.   DOI   ScienceOn
7 Biella GE, Groppetti A, Novelli A, Fernandez-Sanchez MT, Manfredi B, Sotgiu ML. Neuronal sensitization and its behavioral correlates in a rat model of neuropathy are prevented by a cyclic analog of orphenadrine. J Neurotrauma 2003; 20: 593-601.   DOI   ScienceOn
8 Novelli A, Groppetti A, Rossoni G, Manfredi B, FerreroGutierrez A, Perez-Gomez A, et al. Nefopam is more potent than carbamazepine for neuroprotection against veratridine in vitro and has anticonvulsant properties against both electrical and chemical stimulation. Amino Acids 2007; 32: 323-32.   DOI
9 Czuczwar M, Czuczwar K, Cieszczyk J, Kis J, Saran T, Luszczki JJ, et al. Nefopam enhances the protective activity of antiepileptics against maximal electroshock-induced convulsions in mice. Pharmacol Rep 2011; 63: 690-6.   DOI
10 Torres GE, Gainetdinov RR, Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003; 4: 13-25.   DOI   ScienceOn
11 Max MB, Gilron IH. Antidepressants, muscle relaxants, and N-methyl-D-aspartate receptor antagonists. In: Bonica's management of pain. 3rd ed. Edited by Loeser JD, Bonica JJ. Philadelphia (PA), Lippincott Williams & Wilkins. 2001, pp 1710-26.
12 Novelli A, Diaz-Trelles R, Groppetti A, Fernandez-Sanchez MT. Nefopam inhibits calcium influx, cGMP formation, and NMDA receptor-dependent neurotoxicity following activation of voltage sensitive calcium channels. Amino Acids 2005; 28: 183-91.   DOI
13 Park SM, Mangat HS, Berger K, Rosengart AJ. Efficacy spectrum of antishivering medications: meta-analysis of randomized controlled trials. Crit Care Med 2012; 40: 3070-82.   DOI   ScienceOn
14 Bilotta F, Rosa G. Nefopam for severe hiccups. N Engl J Med 2000; 343: 1973-4.
15 Pajot S, Geeraerts T, Leblanc PE, Duranteau J, Benhamou D. Hiccup during weaning from mechanical ventilation: the use of nefopam. Br J Anaesth 2007; 99: 748-9.   DOI   ScienceOn
16 Barrot M. Tests and models of nociception and pain in rodents. Neuroscience 2012; 211: 39-50.   DOI   ScienceOn
17 Jaggi AS, Jain V, Singh N. Animal models of neuropathic pain. Fundam Clin Pharmacol 2011; 25: 1-28.
18 Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. Pain 1987; 30: 103-14.   DOI   ScienceOn
19 Cho SY, Park AR, Yoon MH, Lee HG, Kim WM, Choi JI. Antinociceptive effect of intrathecal nefopam and interaction with morphine in formalin-induced pain of rats. Korean J Pain 2013; 26: 14-20.   DOI   ScienceOn
20 Girard P, Pansart Y, Coppe MC, Gillardin JM. Nefopam reduces thermal hypersensitivity in acute and postoperative pain models in the rat. Pharmacol Res 2001; 44: 541-5.   DOI   ScienceOn
21 Fink KB, Göthert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 2007; 59: 360-417.   DOI
22 Löscher W, Schmidt D. New Horizons in the development of antiepileptic drugs: innovative strategies. Epilepsy Res 2006; 69: 183-272.   DOI   ScienceOn
23 Hoebel BG, Hernandez L, Schwartz DH, Mark GP, Hunter GA. Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications. Ann N Y Acad Sci 1989; 575: 171-91.   DOI
24 Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994; 46: 157-203.
25 Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38: 1083-152.   DOI   ScienceOn
26 Buritova J, Besson JM. Effects of nefopam on the spinal nociceptive processes: a c-Fos protein study in the rat. Eur J Pharmacol 2002; 441: 67-74.   DOI   ScienceOn
27 Evans MS, Lysakowski C, Tramer MR. Nefopam for the prevention of postoperative pain: quantitative systematic review. Br J Anaesth 2008; 101: 610-7.   DOI   ScienceOn
28 Tigerstedt I, Tammisto T, Leander P. Comparison of the analgesic dose-effect relationships of nefopam and oxycodone in postoperative pain. Acta Anaesthesiol Scand 1979; 23: 555-60.   DOI   ScienceOn
29 Dordoni PL, Della Ventura M, Stefanelli A, Iannace E, Paparella P, Rocca B, et al. Effect of ketorolac, ketoprofen and nefopam on platelet function. Anaesthesia 1994; 49: 1046-9.   DOI   ScienceOn
30 Gasser JC, Bellville JW. Respiratory effects of nefopam. Clin Pharmacol Ther 1975; 18: 175-9.   DOI
31 Guindon J, Walczak JS, Beaulieu P. Recent advances in the pharmacological management of pain. Drugs 2007; 67: 2121-33.   DOI   ScienceOn
32 Podranski T, Bouillon TW, Riva T, Kurz AM, Oehmke MJ. Compartmental pharmacokinetics of nefopam during mild hypothermia. Br J Anaesth 2012; 108: 784-91.   DOI   ScienceOn
33 Izzo V, Mariconti P, Tiengo M. Action and effectiveness of nefopam chloride in the control of postoperative shivering. Minerva Anestesiol 1991; 57: 760-2.
34 Kim YA, Kweon TD, Kim M, Lee HI, Lee YJ, Lee KY. Comparison of meperidine and nefopam for prevention of shivering during spinal anesthesia. Korean J Anesthesiol 2013; 64: 229-33.   DOI   ScienceOn
35 Heel RC, Brogden RN, Pakes GE, Speight TM, Avery GS. Nefopam: a review of its pharmacological properties and therapeutic efficacy. Drugs 1980; 19: 249-67.   DOI   ScienceOn
36 Bassett JR, Cairncross KD, Hacket NB, Story M. Studies on the peripheral pharmacology of fenazoxine, a potential antidepressant drug. Br J Pharmacol 1969; 37: 69-78.   DOI   ScienceOn
37 Tobin WE, Gold RH. Nefopam hydrochloride: a novel muscle relaxant. J Clin Pharmacol New Drugs 1972; 12: 230-8.   DOI
38 Bolt AG, Graham G, Wilson P. Stereoselective demethylation of the enantiomers of nefopam, an experimental antidepressant and skeletal muscle relaxant. Xenobiotica 1974; 4: 355-63.   DOI
39 Koe BK. Molecular geometry of inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J Pharmacol Exp Ther 1976; 199: 649-61.
40 Cohen A. Nefopam hydrochloride for pain relief. Curr Ther Res Clin Exp 1974; 16: 184-93.
41 Klotz AL. Long-term safety of Nefopam hydrochloride (Acupan), a new analgesic formulation. Curr Ther Res Clin Exp 1974; 16: 602-8.
42 Workmon FC, Winter L Jr. A clinical evaluation of nefopam hydrochloride (Acupan): a new analgesic. Curr Ther Res Clin Exp 1974; 16: 609-16.
43 Kolodny AL, Winter L Jr. Further clinical evaluations of nefopam hydrochloride, a new analgesic. Curr Ther Res Clin Exp 1975; 17: 519-24.
44 Alfonsi P, Adam F, Passard A, Guignard B, Sessler DI, Chauvin M. Nefopam, a nonsedative benzoxazocine analgesic, selectively reduces the shivering threshold in unanesthetized subjects. Anesthesiology 2004; 100: 37-43.   DOI   ScienceOn
45 Kakkar M, Derry S, Moore RA, McQuay HJ. Single dose oral nefopam for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; (3): CD007442.
46 Gregori-Puigjane E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, et al. Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci U S A 2012; 109: 11178-83.   DOI
47 Moore RA, Derry S, McQuay HJ, Wiffen PJ. Single dose oral analgesics for acute postoperative pain in adults. Cochrane Database Syst Rev 2011; (9): CD008659.
48 Bilotta F, Pietropaoli P, Rosa G. Nefopam for refractory postoperative hiccups. Anesth Analg 2001; 93: 1358-60.   DOI   ScienceOn
49 Cotecchia S, Stanasila L, Diviani D. Protein-protein interactions at the adrenergic receptors. Curr Drug Targets 2012; 13: 15-27.   DOI
50 Laboureyras E, Chateauraynaud J, Richebe P, Simonnet G. Long-term pain vulnerability after surgery in rats: prevention by nefopam, an analgesic with antihyperalgesic properties. Anesth Analg 2009; 109: 623-31.   DOI   ScienceOn